Baxter graft sealer gets FDA approval

DEERFIELD -- Baxter Healthcare Corp. on Thursday announced the U.S. Food and Drug Administration's approval of Artiss, the first slow-setting fibrin sealant for use in adhering skin grafts in adult and pediatric burn patients. Artiss allows for the delayed setting of skin grafts for about 60 seconds, verses five to 10 seconds with current grafts. It allows skin grafts to be fixed without the use of staples or sutures, the Deerfield-based Baxter said.